Skip to content

Kiniksa Pharmaceuticals International

US · KNSA #1938 by market cap Listed 2018
77.96 +0.87 +1.13%
Live - 5344 symbols - heartbeat 502s ago · 2026-10-07 19:54
After-hours 78.50 +0.69%
Market cap
6.08B
P/B
9.30
EPS
0.75
Reader sentiment Are you bullish or bearish on KNSA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $74
    Market Newswire · 2026/7/13
  • Rating change
    A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $57 to $71
    Market Newswire · 2026/4/29
  • CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $98
    Market Newswire · 2026/8/13
  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53
    Market Newswire · 2026/2/26
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $50
    Market Newswire · 2026/1/13
  • Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/6/29
  • Rating change
    Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $50
    Market Newswire · 2025/12/12
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53
    Market Newswire · 2026/2/25
  • Rating change
    TD Cowen Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/2/25
  • A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $87 to $107
    Market Newswire · 2026/7/30
  • Wells Fargo Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $87
    Market Newswire · 2026/9/30
  • Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $90
    Market Newswire · 2026/7/30
  • Rating change
    Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $75
    Market Newswire · 2026/7/23
  • Rating change
    CCORF Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $62
    Market Newswire · 2026/2/19
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $58
    Market Newswire · 2026/4/16
  • Rating change
    Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/1/30
  • Rating change
    Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $59
    Market Newswire · 2026/4/29
  • Rating change
    J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/3/14
  • Rating change
    CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/2/26
  • Rating change
    J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/5/4

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.